Heparanase expression in Langerhans cell histiocytosis

Authors

  • Rina Dvir MD,

    Corresponding author
    1. Department of Pediatric Hemato-Oncology, Tel-Aviv Sourasky Medical Center affiliated to the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    • Correspondence to: Rina Dvir, Department of Pediatric Hemato-Oncology, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv 64239, Israel.

      E-mail: rinad@tasmc.health.gov.il

    Search for more papers by this author
  • Israel Vlodavsky PhD,

    1. Cancer and Vascular Biology Research Center, The Rappaport Faculty of Medicine, Technion, Haifa, Israel
    Search for more papers by this author
  • Neta Ilan PhD,

    1. Cancer and Vascular Biology Research Center, The Rappaport Faculty of Medicine, Technion, Haifa, Israel
    Search for more papers by this author
  • Menachem Bitan MD, PhD,

    1. Department of Pediatric Hemato-Oncology, Tel-Aviv Sourasky Medical Center affiliated to the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    Search for more papers by this author
  • Josephine Issacov MD,

    1. Department of Pediatric Hemato-Oncology, Tel-Aviv Sourasky Medical Center affiliated to the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    Search for more papers by this author
  • Ronit Elhasid MD

    1. Department of Pediatric Hemato-Oncology, Tel-Aviv Sourasky Medical Center affiliated to the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
    Search for more papers by this author

  • Conflict of interest: Nothing to declare.

Abstract

Heparanase is an endo-beta D-glucuronidase capable of cleaving heparan sulfate side chains, yielding heparan sulfate fragments. Heparanase activity has been correlated with the metastatic potential of tumor-derived cells, angiogenesis, autoimmunity and inflammation. We performed a study of heparanase expression in specimens obtained from patients with Langerhans cell histiocytosis (LCH). Paraffin embedded slides from 25 patients were studied by immunohistochemistry for heparanase. Most patients had positive staining for heparanase (21/25). There was no positive association with severity of disease and other clinical characteristics. Further studies are required to clarify the role of heparanase in the pathogenesis of LCH. Pediatr Blood Cancer 2014; 61:1883–1885. © 2014 Wiley Periodicals, Inc.

Ancillary